Cardiovascular Risk: From Epigenetics to Pharmacotherapy
Wednesday, June 19, 2013, Noon CDT
|Moderators:||Robert O. Bonow, M.D., FAHA|
Northwestern University Feinberg School of Medicine
Past AHA President and Chair of the Emerging Science Series Committee
Christopher J. O'Donnell, M.D., MPH
National Heart, Lung and Blood Institute and NHLBI Framingham Heart Study
Neil J. Stone, M.D., FAHA,
Kiran Musunuru, M.D., Ph.D., M.P.H.,
Vasan Ramachandran M.D.,
|Presentations:||CPT1A Methylation is a Novel Epigenetic Marker of Cardiovascular Risk |
Stella Aslibekyan, Ph.D., University of Alabama at Birmingham, Birmingham, Ala.
Summary Slide | News Release | Abstract in Circulation | Review Article: Cardiovascular Epigenetics
The Incidence of Kidney Injury for Patients Treated with Intensive versus Less Potent Statin Therapy After an Acute Coronary Syndrome
Amy Sarma, M.D., Brigham and Women's Hospital, Boston, Mass.
Summary Slide | News Release | Abstract in Circulation
No CME/CE credit for this activity is provided.